Last reviewed · How we verify
PEG Asparaginase at six weeks interval
PEG Asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine.
PEG Asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine. Used for Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy.
At a glance
| Generic name | PEG Asparaginase at six weeks interval |
|---|---|
| Also known as | Oncaspar (PEG-Asparaginase) |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Enzyme (asparagine depleting agent) |
| Target | Asparagine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. Acute lymphoblastic leukemia (ALL) cells are often asparagine synthetase-deficient and depend on exogenous asparagine for survival. By depleting circulating asparagine, the drug induces apoptosis in leukemic blasts while sparing most normal cells that can synthesize asparagine endogenously. PEGylation extends the drug's half-life, allowing for less frequent dosing intervals.
Approved indications
- Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy
Common side effects
- Hypersensitivity reactions
- Pancreatitis
- Thrombosis
- Hepatotoxicity
- Coagulopathy
- Nausea and vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: